Drug Profile
Trifarotene - Galderma/Mayne Pharma
Alternative Names: AKLIEF; CD-5789Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Galderma
- Developer Galderma; Mayne Pharma Group
- Class Antiacnes; Antineoplastics; Benzoic acids; Keratolytics; Pyrrolidines; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Retinoic acid receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acne vulgaris
- Phase II Ichthyosis
- No development reported Cutaneous T-cell lymphoma
Most Recent Events
- 13 Sep 2021 Mayne Pharma Group terminates a phase II trial in Ichthyosis (In adolescents, In adults, In the elderly) in Australia, Canada, France, Germany, Israel, Ukraine, Spain, United Kingdom and USA, due to futile outcome (Topical) (EudraCT2018-003272-12) (NCT03738800)
- 18 Jan 2021 Registered for Acne vulgaris (In adolescents, In children, In adults) in Australia (Topical, Cream)
- 23 Dec 2019 Galderma completes a phase III trial in Acne vulgaris (In children, In adolescents, In adults) in USA (NCT03915860)